Completed PHASE3 INTERVENTIONAL 1-arm NCT00380367

Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)

Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India

Sponsor: Merck Sharp & Dohme LLC

Conditions Papillomavirus Infections

Interventions Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine

Updated 9 times since 2017 Last updated: May 2, 2023 Started: May 3, 2007 Primary completion: Feb 4, 2008 Completion: Feb 4, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Papillomavirus Infections and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 9 recorded versions since 2007 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2023 — Jul 2024 [monthly]

Completed PHASE3
Jun 2022 — Jun 2023 [monthly]

Completed PHASE3
Jan 2021 — Jun 2022 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jun 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Jun 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.